A Phase IIb Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance.

Trial Profile

A Phase IIb Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2015

At a glance

  • Drugs Dolutegravir (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms VIKING
  • Sponsors GlaxoSmithKline; ViiV Healthcare
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 27 Dec 2012 Planned end date changed from 1 Sep 2015 to 1 Jan 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top